A case of antisynthetase syndrome in a rheumatoid arthritis patient with anti-PL-12 antibody following treatment with etanercept.
スポンサーリンク
概要
- 論文の詳細を見る
In our earlier study, we had reported the case of a patient with rheumatoid arthritis (RA), who had anti-Jo-1 antibodies. This patient had received etanercept (ETN) therapy for RA, after which she had developed overt polymyositis (PM). Although various autoimmune phenomena, including lupus-like diseases, vasculitides, or psoriatic skin lesions, are associated with antitumor necrosis factor (TNF) therapy, the development of PM/dermatomyositis (DM) or antisynthetase syndrome following anti-TNF therapy is extremely rare. Here, we report a case of an RA patient with anti-PL-12 antibodies, who received ETN therapy and subsequently developed the antisynthetase syndrome. She recovered when ETN therapy was withdrawn and high-dose corticosteroid was administered. To date, there have been only five reported cases of RA patients with anti-Jo-1 antibodies who developed overt PM/DM following anti-TNF therapy and only one case of antisynthetase syndrome in an RA patient with anti-PL-7 antibodies. Our patients and the abovementioned reports strongly suggest that onset of overt PM/DM or antisynthetase syndrome in RA patients with anti-aminoacyl tRNA synthetase antibodies is associated with anti-TNF therapy.
論文 | ランダム
- 1P141 アクトミオシン系に於けるアクチン繊維の周辺環境(筋肉(筋蛋白・収縮)))
- コイ科魚類における交雑実験〔英文〕-2-
- ブロノポールを用いたアユ卵の水カビ病防除
- 神奈川県におけるコイヘルぺスウイルス(KHV)の検出
- ESTABLISHMENT OF MONOCLONAL ANTIBODY TO ONCORHYNCHUS MASOU VIRUS (OMV)